• 1
    Destefano N, Matthews P, Antel JP, Preul M, Francis G, Arnold DL. Chemical pathology of acute demyelinating lesions and its correlations with disability. Ann. Neurol. 1995; 8: 901909.
  • 2
    McGuire PK, Bench CJ, Frith CD, Marks IM, Frackowiak RS, Dolan RJ. Functional anatomy of obsessive–compulsive phenomena. Br. J. Psychiatry 1994; 164: 459468.
  • 3
    Adler CM, McDonough-Ryan P, Sax KW, Holland SK, Arndt S, Strakowski SM. fMRI of neuronal activation with symptom provocation in unmedicated patients with obsessive compulsive disorder. J. Psychiatr. Res. 2000; 34: 317324.
  • 4
    Nagy J, Zambo K, Decsi L. Anti-anxiety action of diazepam after intra-amygdaloid application in the rat. Neuropharmacol 1979; 18: 573576.
  • 5
    Gonzalez LE, Andrews N, File SE. 5-HT1A and benzodiazepine receptors in the basolateral amygdala modulate anxiety in the social interaction test, but not in the elevated plus-maze. Brain Res. 1996; 732: 145153.
  • 6
    Zangrossi H Jr, Viana MB, Graeff FG. Anxiolytic effect of intra-amygdala injection of midazolam and 8-hydroxy-2-(di-n-propylamino)tetralin in the elevated T-maze. Eur. J. Pharmacol. 1999; 369: 267270.
  • 7
    Ebert D, Speck O, König A, Berger M, Hennig J, Hohagen F. 1H-magnetic resonance spectroscopy in obsessive-compulsive disorder: Evidence for neuronal loss in the cingulate gyrus and the right striatum. Psychiatry Res. 1997; 74: 173176.
  • 8
    Bartha R, Stein MB, Williamson PC et al. A short echo 1H spectroscopy and volumetric MRI study of the corpus striatum in patients with obsessive-compulsive disorder and comparison subjects. Am. J. Psychiatry 1998; 155: 15841591.
  • 9
    Rosenberg DR, Amponsah A, Sullivan A, MacMillan S, Moore GJ. Increased medial thalamic choline in pediatric obsessive–compulsive disorder as detected by quantitative in vivo spectroscopic imaging. J. Child Neurol. 2001; 16: 636641.
  • 10
    Smith EA, Russell A, Lorch E et al. Increased medial thalamic choline found in pediatric patients with obsessive–compulsive disorder versus major depression or healthy control subjects: A magnetic resonance spectroscopy study. Biol. Psychiatry 2003; 54: 13991405.
  • 11
    Rosenberg DR, MacMaster FP, Keshavan MS, Fitzgerald KD, Stewart CM, Moore GJ. Decrease in caudate glutamatergic concentrations in pediatric obsessive–compulsive disorder patients taking paroxetine. J. Am. Acad. Child Adolesc. Psychiatry 2000; 39: 10961103.
  • 12
    Russell A, Cortese B, Lorch E et al. Localized functional neurochemical marker abnormalities in dorsolateral prefrontal cortex in pediatric obsessive–compulsive disorder. J. Child Adolesc. Psychopharmacol. 2003; 13: S31S38.
  • 13
    Sumitani S, Harada M, Kubo H, Ohmori T. Proton magnetic resonance spectroscopy reveals an abnormality in the anterior cingulate of a subgroup of obsessive–compulsive disorder patients. Psychiatry Res. 2007; 154: 8592.
  • 14
    Corapcioglu A, Aydemir Ö, Yıldız M et al. DSM-IV Eksen I Bozuklukları (SCID-I) İçin Yapılandırılmış Klinik Görüşme, Klinik Versiyon. Hekimler Yayın Birliği, Ankara, 1999.
  • 15
    Duvernoy HM, Cabanis EA. The Human Brain: Surface, Three-Dimensional Sectional Anatomy, and MRI. Springer-Verlag, New York, 1991.
  • 16
    Talairach J, Tournoux P. Coplanar Stereotaxic Atlas of the Human Brain. Thieme Medical Publishers, New York, 1998.
  • 17
    Fitzgerald KD, Moore GJ, Paulson LA, Stewart CM, Rosenberg DR. Proton spectroscopic imaging of the thalamus in treatment-naive pediatric obsessive–compulsive disorder. Biol. Psychiatry 2000; 47: 174182.
  • 18
    Steingard RJ, Yurgelun-Todd DA, Hennen J et al. Increased orbitofrontal cortex levels of choline in depressed adolescents as detected by in vivo proton magnetic resonance spectroscopy. Biol. Psychiatry 2000; 48: 10531061.
  • 19
    Exton JH. Phosphatidylcholine breakdown and signal transduction. Biochim. Biophys. Acta 1994; 1212: 2642.